A variety of consumable plant-derived phytochemicals exhibit nutraceutical properties because they produce physiological benefits and combat disease processes. Emerging evidence suggests that widely accessible and safe organic polyphenolic phytochemicals, in particular, treat depression at much lower concentrations than clinical doses of classical drugs. Structurally similar polyphenolics such as curcumin, resveratrol, and proanthocyanidins exhibit antioxidant and immunomodulatory properties and recent research suggests that they also modulate hypothalamic-pituitary-adrenal (HPA) axis activity, serotonergic transmission and hippocampal neurogenesis (perhaps via their effects on serotonin and HPA activity). These data tempt speculation that polyphenolic compounds could also combat age-related cognitive decline, which is often accompanied by depression and potentially by reduced levels of hippocampal neurogenesis. Here we review the relationships between dysregulation of these systems and age-related cognitive decline. We then suggest that this group of structurally similar polyphenolic compounds may be particularly promising therapeutic leads for age-related cognitive decline and depression because they modulate these processes.

1.
Foster TC: Biological markers of age-related memory deficits: Treatment of senescent physiology. CNS Drugs 2006;20:153–166.
2.
Lupien SJ, McEwen BS, Gunnar MR, Heim C: Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci 2009;10:434–445.
3.
Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bellia F, Bates TE, Giuffrida Stella AM, Schapira T, Dinkova Kostova AT, Rizzarelli E: Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res 2008;33:2444–2471.
4.
Berton O, Nestler EJ: New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137–151.
5.
Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, Kupfer DJ, Reynolds CF: Serotonin in aging, late-life depression, and Alzheimer’s disease: the emerging role of functional imaging. Neuropsychopharmacology 1998;18:407–430.
6.
Lazarov O, Mattson MP, Peterson DA, Pimplikar SW, van Praag H: When neurogenesis encounters aging and disease. Trends Neurosci 2010;33:569–579.
7.
Carr GV, Lucki I: The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl) 2011;213:265–287.
8.
Lanfumey L, Mongeau R, Cohen-Salmon C, Hamon M: Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci Biobehav Rev 2008;32:1174–1184.
9.
Xu Y, Zhang C, Wang R, Govindarajan SS, Barish PA, Vernon MM, Fu C, Acharya AP, Chen L, Boykin E, Yu J, Pan J, O’Donnell JM, Ogle WO: Corticosterone induced morphological changes of hippocampal and amygdaloid cell lines are dependent on 5-HT7 receptor related signal pathway. Neuroscience 2011;182:71–81.
10.
Deng W, Aimone JB, Gage FH: New neurons and new memories. How does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 2010;11:339–350.
11.
Speisman R, Kumar A, Rani A, Foster TC, Ormerod BK: Environmental enrichment restores neurogenesis and rapid acquisition in aged rats. Neurobiol Aging 2012 Jul 11 [Epub ahead of print].
12.
Dupret D, Revest JM, Koehl M, Ichas F, De Giorgi F, Costet P, Abrous DN, Piazza PV: Spatial relational memory requires hippocampal adult neurogenesis. PLoS One 2008;3:e1959.
13.
Eisch AJ, Cameron HA, Encinas JM, Meltzer LA, Ming GL, Overstreet-Wadiche LS: Adult neurogenesis, mental health, and mental illness. Hope or hype? J Neurosci 2008;28:11785–11791.
14.
Voleti B, Duman RS: The roles of neurotrophic factor and wnt signaling in depression. Clin Pharmacol Ther 2012;91:333–338.
15.
David DJ, Wang J, Samuels BA, Rainer Q, David I, Gardier AM, Hen R: Implications of the functional integration of adult-born hippocampal neurons in anxiety-depression disorders. Neuroscientist 2010;16:578–591.
16.
Schmidt HD, Shelton RC, Duman RS: Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011;36:2375–2394.
17.
Xu Y, Barish PA, Pan J, Ogle WO, O’Donnell JM: Animal models of depression and neuroplasticity: assessing drug action in relation to behavior and neurogenesis. Methods Mol Biol 2012;829:103–124.
18.
Schaffer S, Asseburg H, Kuntz S, Muller WE, Eckert GP: Effects of polyphenols on brain ageing and Alzheimer’s disease: focus on mitochondria. Mol Neurobiol 2012, E-pub ahead of print.
19.
Linde K, Berner MM, Kriston L: St John’s wort for major depression. Cochrane Database Syst Rev 2008:CD000448.
20.
Izzo AA, Ernst E: Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69:1777–1798.
21.
Wurtman RJ, Cansev M, Sakamoto T, Ulus I: Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr Rev 2010;68(suppl 2):S88–S101.
22.
Bhutani MK, Bishnoi M, Kulkarni SK: Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav 2009;92:39–43.
23.
Xu Y, Ku B, Cui L, Li X, Barish PA, Foster TC, Ogle WO: Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1a mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 2007;1162:9–18.
24.
Xu Y, Wang Z, You W, Zhang X, Li S, Barish PA, Vernon MM, Du X, Li G, Pan J, Ogle WO: Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol 2010;20:405–413.
25.
Xu Y, Li S, Chen R, Li G, Barish PA, You W, Chen L, Lin M, Ku B, Pan J, Ogle WO: Antidepressant-like effect of low molecular proanthocyanidin in mice: involvement of monoaminergic system. Pharmacol Biochem Behav 2010;94:447–453.
26.
Wang R, Li YH, Xu Y, Li YB, Wu HL, Guo H, Zhang JZ, Zhang JJ, Pan XY, Li XJ: Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:147–153.
27.
Moriya J, Chen R, Yamakawa J, Sasaki K, Ishigaki Y, Takahashi T: Resveratrol improves hippocampal atrophy in chronic fatigue mice by enhancing neurogenesis and inhibiting apoptosis of granular cells. Biol Pharm Bull 2011;34:354–359.
28.
Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA: Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 2009;159:993–1002.
29.
Chao J, Li H, Cheng KW, Yu MS, Chang RC, Wang M: Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. J Nutr Biochem 2010;21:482–489.
30.
Maher P: A comparison of the neurotrophic activities of the flavonoid fisetin and some of its derivatives. Free Radic Res 2006;40:1105–1111.
31.
Ebrahimi A, Schluesener H: Natural polyphenols against neurodegenerative disorders: potentials and pitfalls. Ageing Res Rev 2012;11:329–345.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.